Is Luoshengquan Entrectinib?

Luo Shengquan and Entrectinib (Entrectinib) are the same drug. Its English name is Entrectinib, and Luo Shengquan is its trade name in the Chinese market.

Enrectinib is an anti-tumor targeted drug targetingNTRK fusion mutant solid tumors and ROS1-positive non-small cell lung cancer (NSCLC). It is the first generation TRK inhibitor and a specific tyrosine kinase inhibitor that has inhibitory effects on cancer cells of various tumors containingNTRK, ROS1 and ALK fusion genes. It can cross the blood-brain barrier and cause the death of ROS1-positive or NTRK-positive cancer cells by blocking the activity of ROS1 and NTRK kinases, thereby inhibiting the growth of cancer cells.

Enrectinib has been approved in many countries around the world for the treatment of ROS1-positive non-small cell lung cancer and NTRK fusion solid tumors. It has good efficacy especially in patients with brain metastases. Entrectinib can be used for treatment of adults and pediatric patients with solid tumors aged 12 years and older who are diagnosed as carrying a neurotrophic tyrosine receptor kinase (NTRK) fusion gene that does not include known acquired resistance mutations, or who have locally advanced or metastatic disease or when surgical resection may lead to severe complications, or when there is no satisfactory alternative treatment or previous treatment has failed.

However, entrectinib may also cause side effects. The most common adverse reactions are fatigue, constipation, dysgeusia, edema, dizziness, diarrhea, nausea, dysesthesia, dyspnea, myalgia, cognitive impairment, weight gain, cough, vomiting, pyrexia, joint pain, and visual impairment. Therefore, patients need to pay special attention to changes in their condition while taking entrectinib and how to effectively manage these changes.